USPTO serial 86857807
V VIVA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- REGAN, JOHN B
- Law office
- TMO LAW OFFICE 113 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with V VIVA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Gina Lupino
GINA LUPINO VOYER LAW CORPORATION403 - 134 Abbott StreetVancouver, BC, V6B 2K4CANADAGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Skin cleansing lotions; skin clarifiers and skin masks | ACTIVE | — |
| 005 | Skin emollient preparations, hair care preparations and skin care preparations, namely, dermatologicals, antibiotic tissue healants, anti-inflammatory and antibacterial ointments, corticosteroid ointments and creams, antiinfective ointments and creams, scabicides; anti-viral ointments and creams; full line of pharmaceutical preparations and substances, namely, pharmaceutical preparations and substances for the treatment, alleviation and/or prevention of gastro-intestinal disorders, disorders of the central nervous system, disorders of the respiratory system, heart conditions and other disorders of the cardiovascular system, and migraines and other forms of headache; analgesics; antivirals; anaesthetics; anti-infectives; anti-inflammatories; antibiotics; antidepressants; broncho-dilators; anti-cancer preparations; medicated lotions for the skin and hair; decongestants and anti-histamines; muscle relaxants; anti-emetics; immunosuppressive agents; antispasmodic agents, antiepileptic agents; cardiotonics; scabicides; anti-malarials; cough suppressants; cough and cold preparations; expectorants; anti-leukemic agents; anti-arrhythmics; dermatologicals; tissue healants; lung surfactants; vasopressors; ophthalmic and optic agents; antitumour agents; antidotes to digitalis poisoning; preparations for treatment of digoxin and digitoxin intoxication; antineoplastic agents; antiprotozoal agents; nondepolarizing skeletal neuromuscular blocking agents; preparations for treatment of gout; xanthine oxidase inhibitors; preparations for cessation of smoking; preparations for treatment of Parkinson's disease; preparations for treatment of hypothyroidism; full line of nutraceutical preparations and substances, namely, extracts or isolates from plant, alga, fungus, non-human animal material, bacterium (including spirulina and non-living, e.g. tyndallized bacteria), namely, enzymes, vitamins, minerals, amino acids, essential fatty acids, synthetic duplicates, probiotics, homeopathic medicines; probiotics, namely, acidophilus, bifidobacterium and lactobacillus; vitamin compounds, namely, vitamin supplements, vitamins, multi-vitamins, vitamin compounds with minerals, vitamin compounds with iron; mineral preparations, namely, minerals; nutritional, dietary and herbal supplements and herbal preparations, namely, semen platycladi, radix polygalae, indole-3-carbionol, 5-hydroxy-L-tryptophan, echinacea, bilberry, cascara sagrada, celery seed, cranberry, nettle root, uva ursi, dandelion root, devil's claw, feverfew, ginger root, ginkgo biloba, grapeseed, resveratrol, citrus bioflavonoids, green tea, hawthorn, horse chestnut, milk thistle, olive leaf, panax ginseng, saw palmetto, siberian ginseng, silica, St. John's Wort, valerian, lutein, zeaxanthin, cayenne, hawaiian spirulina, swedish bitters; fatty supplements, namely, flax seed oil and fish derived oils; glucosamine, chondroitin, methyl-sulfonyl-methane, whey, creatine; herbal products, namely, herbals; standardized herbal extracts, namely, semen platycladi, radix polygalae, echinacea, bilberry, cascara sagrada, celery seed, cranberry, nettle root, uva ursi, dandelion root, devil's claw, feverfew, ginger root, ginkgo biloba, grapeseed, green tea, hawthorn, horse chestnut, milk thistle, olive leaf, panax ginseng, saw palmetto, siberian ginseng, silica, St. John's Wort, valerian, lutein, zeaxanthin, cayenne, hawaiian spirulina, swedish bitters; nutraceuticals, namely, dietary supplements and herbal products, namely, folic acid, lutein, zeaxanthin, lycopene, acidophilus, bee pollen, beta-carotene, bromelain, choline, flavonoids, grape seed extract, kelp, lecithin, lipoic acid, mushroom extracts, SAM-e, crustacean exoskeleton, soy protein, spirulina; amino acid compounds, namely, NAC (n-acetyl cysteine) and L-glutamine; sports nutrition products, namely, whey proteins and creatines; antioxidants, namely, vitamins C and E, vitamin A, beta-carotene, selenium and carotenoids; cosmeceuticals, namely, medicinal herbal creams, lotions and oils for treatment of skin damage and repair; food products, namely, herbs, greens, dehydrated foods derived from plants, namely, vegetable and fruit powder, vegetable protein and greens, natural flavors derived from fruits, dietary fiber; evening primrose oil, salmon oil, whey, creatine; nutritional products and natural health products, namely, carotenoids, enzymes, alfalfa leaf, conjugated linoleic acid, apple cider vinegar, fenugreek seed, coenzyme Q10, alpha lipoic acid, pine bark extract, crustacean exoskeleton, garlic, kelp, pectin, policosanol, flaxseed oil, pumpkin seed oil, borage oil, perilla seed oil, salmon oil, evening primrose oil, tuna oil, thyme oil, peppermint oil complex, lecithin, phosphatidyl choline, soya lecithin granules, phosphatidyl serine, bee pollen, bee propolis, royal jelly, soy isoflavones complex, chasteberry, echinacea | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 10, 2021 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 10, 2021 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 20, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 20, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 20, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 28, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 28, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 21, 2020 | ALIE | ASSIGNED TO LIE | — |
| Jul 14, 2020 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jan 17, 2020 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jan 17, 2020 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jan 17, 2020 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jan 6, 2020 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Aug 1, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 1, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 20, 2019 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 20, 2019 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 20, 2019 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 13, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 13, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 11, 2019 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Dec 14, 2018 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Dec 14, 2018 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Dec 14, 2018 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Nov 29, 2018 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 29, 2018 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 29, 2018 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 29, 2018 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 8, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 8, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 7, 2018 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Dec 7, 2017 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Dec 7, 2017 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Dec 7, 2017 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Nov 17, 2017 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 3, 2017 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 3, 2017 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 3, 2017 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 1, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 1, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 28, 2017 | ALIE | ASSIGNED TO LIE | — |
| Apr 20, 2017 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Apr 20, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 27, 2016 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Oct 27, 2016 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Oct 27, 2016 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Oct 21, 2016 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Apr 19, 2016 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 19, 2016 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 19, 2016 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 12, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 29, 2016 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jan 21, 2016 | ALIE | ASSIGNED TO LIE | — |
| Jan 7, 2016 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jan 6, 2016 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jan 5, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 30, 2015 | NWAP | NEW APPLICATION ENTERED | — |